We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Werfen and Thermo Fisher Enter Into Worldwide Distributor Agreement for Hemostasis Testing Workcell

By LabMedica International staff writers
Posted on 05 May 2023
Print article
Image: HemoCell Specialized Lab Automation is a customizable and fully automated workcell for hemostasis testing (Photo courtesy of Werfen)
Image: HemoCell Specialized Lab Automation is a customizable and fully automated workcell for hemostasis testing (Photo courtesy of Werfen)

Werfen (Barcelona, Spain) has entered into a new long-term, exclusive partnership agreement with Thermo Fisher Scientific (Waltham, MA, USA) to globally distribute the TCAutomation laboratory automation system, specifically tailored for hemostasis diagnostics. This agreement, a follow-up to their exclusive contract signed in 2015, allows Werfen to continue offering HemoCell Specialized Lab Automation, which has the largest global installed base of hemostasis automation workcells.

HemoCell streamlines laboratory workflow by integrating all stages of testing. It comprises Werfen's ACL TOP Family 50 Series Hemostasis Testing Systems and HemoHub Intelligent Data Manager, paired with Thermo Fisher's TCAutomation system. This combination standardizes sample processing, ensuring consistent turnaround times for routine and urgent samples. This efficiency frees up laboratory staff, improving overall lab efficiency and quality of work. Ultimately, HemoCell contributes to improving the quality of care while minimizing costs.

The TCAutomation laboratory automation system is designed to provide truly efficient workflow for laboratories through its modularity, flexibility, and connectivity. It aids in managing escalating workloads and improving quality. By offering flexible and cost-effective solutions, it automates the most labor-intensive pre- and post-analytical tasks. Its open concept enables direct interfaces with a broad range of analyzers. The TCAutomation system can be easily expanded with additional modules, thereby helping laboratories adapt to future needs and requirements and boost efficiency, productivity, and safety.

"This significant continuation of our long-term distribution agreement is a testament to the strength of our partnership with Thermo Fisher Scientific," said Remo Tazzi, Vice President, Worldwide Marketing and Service, Hemostasis and Acute Care Diagnostics at Werfen. "It also speaks volumes about the success of HemoCell, and the quality of Werfen's workflow experts, their innovative tools and processes, and the value they offer hospital laboratories around the world."

Related Links:
Werfen 
Thermo Fisher Scientific 

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Chagas Disease Test
LIAISON Chagas
New
Hemoglobin/Haptoglobin Assay
IDK Hemoglobin/Haptoglobin Complex ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more